Zheng Quan Shi Bao Wang·2025-12-25 00:19Core Viewpoint - New Ji Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with Guotai Junan as the exclusive sponsor [1] Group 1: Technology Platforms - The company has developed two core technology platforms: soluble microneedle formulation technology platform and nasal inhalation formulation technology platform [1] Group 2: Core Products - The first core product is a dexmedetomidine microneedle patch aimed at providing a painless and convenient transdermal delivery method for preoperative sedation in both children and adult patients. This product is currently in Phase IIa clinical trials for pediatric patients in China, with Phase II trials for adult patients expected to begin in Q1 2026 [1] - The second core product, XJN010, is based on the nasal inhalation formulation platform and aims to deliver drugs rapidly through the nasal-brain pathway. It is currently in Phase II clinical trials in China [1] Group 3: Pipeline Products - The company has two additional products in the preclinical stage: XJN1102 (a soluble microneedle patch for adult type 2 diabetes and weight control, with plans to submit an IND application to NMPA and FDA in Q4 2026) and XJN2503 (a nasal inhalation formulation for the relief and prevention of chemotherapy-related nausea and vomiting, also planned for IND submission to NMPA in Q4 2026) [1]